In the last decade, scientific research showed exponential growth in scientific publications on exosomes. According to a March 16, 2016 press release, BCC Research reveals in its new report that these tiny sub-cellular vesicles may offer unlimited potential in diagnostics and therapeutics, especially in oncology treatments. The new report is titled Exosome Diagnostics and Therapeutics: Global Markets (BIO149A) analyzes the technologies for exosome diagnostics and therapeutics with breakdowns of new and existing diagnostic methods. Analyses of global market drivers and trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021 also are provided. Exosomes are small membrane-bounded sacs/vesicles (approximately 30-100 nm in diameter), that are released by both healthy and cancerous cells. Substances from cell cytoplasm, such as genomic DNA, various RNA species, proteins, and lipids are encapsulated into exosomes and are shed into the extracellular environment. Research has showed that all fluids in the human body contain exosomes, which can transfer cytoplasmic ingredients to other cells either locally or at distant sites. Once reaching the recipient cells, cytoplasmic ingredients can alter cell biology. The market for the exosome approach can be divided into three main categories: diagnostics, therapeutics, and research tools sectors. The global market should reach about $16.1 million and more than $111 million in 2016 and 2021, respectively, reflecting a five-year compound annual growth rate (CAGR) of 47.3%. Diagnostics as a segment should remain the largest and fastest-growing sector, growing from $10 million in 2016 to $100 million in 2021, demonstrating a five-year CAGR of 58.5%.
Login Or Register To Read Full Story